TRUQAP is taken in combination with a hormone therapy called abiraterone, along with prednisone, which is a steroid. These medicines work together to block sources of cancer growth.

The first targeted combination therapy of its kind

TRUQAP is taken in combination with a hormone therapy called abiraterone.* These medicines work together to block sources of cancer growth.

In metastatic prostate cancer with PTEN deficiency, there are two different sources in the body that cause cancer cells to grow and spread. TRUQAP + abiraterone* work together by blocking both sources of tumor growth at the same time.

  • TRUQAP blocks cancer signals in one of those sources from telling cancer cells to grow and spread
  • Abiraterone* lowers testosterone, a hormone that fuels tumor growth

*Abiraterone is taken with prednisone.

Metastatic=cancer that has spread to other parts of the body.

The First Targeted Combination Therapy of its Kind The First Targeted Combination Therapy of its Kind
iconicon

This combination targets two important sources of cancer growth.

Find out if TRUQAP could be right for you. Talk to your doctor about biomarker testing.

mPC=metastatic prostate cancer.

back to top button